Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CRL NASDAQ:EXAS NASDAQ:INCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRLCharles River Laboratories International$181.95+0.1%$170.48$132.58▼$228.88$8.98B1.44939,732 shs1.34 million shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/AINCYIncyte$97.77-2.1%$95.61$57.77▼$112.29$19.53B0.791.74 million shs1.02 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRLCharles River Laboratories International-1.81%+11.13%+8.00%-0.90%+57.91%EXASExact Sciences0.00%0.00%0.00%+2.19%+94.08%INCYIncyte+2.44%+0.76%+5.26%-2.83%+67.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRLCharles River Laboratories International$181.95+0.1%$170.48$132.58▼$228.88$8.98B1.44939,732 shs1.34 million shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/AINCYIncyte$97.77-2.1%$95.61$57.77▼$112.29$19.53B0.791.74 million shs1.02 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRLCharles River Laboratories International-1.81%+11.13%+8.00%-0.90%+57.91%EXASExact Sciences0.00%0.00%0.00%+2.19%+94.08%INCYIncyte+2.44%+0.76%+5.26%-2.83%+67.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRLCharles River Laboratories International 2.63Moderate Buy$205.3612.86% UpsideEXASExact Sciences 1.95Reduce$92.13-12.19% DownsideINCYIncyte 2.43Hold$104.266.64% UpsideCurrent Analyst Ratings BreakdownLatest INCY, CRL, and EXAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026INCYIncyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$135.004/29/2026INCYIncyte OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$84.00 ➝ $90.004/29/2026INCYIncyte Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$120.00 ➝ $123.004/20/2026CRLCharles River Laboratories International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/15/2026INCYIncyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$135.004/14/2026CRLCharles River Laboratories International BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$200.00 ➝ $210.004/14/2026CRLCharles River Laboratories International Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$215.004/14/2026CRLCharles River Laboratories International Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageModerate Buy$215.004/13/2026CRLCharles River Laboratories International JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$165.00 ➝ $160.004/8/2026CRLCharles River Laboratories International EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/1/2026INCYIncyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRLCharles River Laboratories International$4.02B2.24$21.53 per share8.45$64.39 per share2.83EXASExact Sciences$3.25B6.17$1.27 per share82.83$12.58 per share8.34INCYIncyte$5.14B3.80$6.20 per share15.77$28.15 per share3.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRLCharles River Laboratories International-$144.34M-$2.96N/A15.142.24-3.59%15.60%6.88%5/7/2026 (Estimated)EXASExact Sciences-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%5/7/2026 (Estimated)INCYIncyte$1.29B$7.0813.8112.280.9226.71%26.66%19.77%N/ALatest INCY, CRL, and EXAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CRLCharles River Laboratories International$1.96$2.06+$0.10-$0.30$977.46 million$995.83 million4/28/2026Q1 2026INCYIncyte$1.38$1.81+$0.43$1.47$1.22 billion$1.27 billion2/18/2026Q4 2025CRLCharles River Laboratories International$2.33$2.39+$0.06-$5.62$986.98 million$994.23 million2/13/2026Q4 2025EXASExact Sciences$0.08-$0.21-$0.29-$0.45$860.59 million$878.38 million2/10/2026Q4 2025INCYIncyte$1.96$1.80-$0.16$1.46$1.35 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRLCharles River Laboratories InternationalN/AN/AN/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRLCharles River Laboratories International0.671.291.02EXASExact Sciences0.972.432.17INCYIncyte0.013.683.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRLCharles River Laboratories International98.91%EXASExact Sciences88.82%INCYIncyte96.97%Insider OwnershipCompanyInsider OwnershipCRLCharles River Laboratories International1.30%EXASExact Sciences1.20%INCYIncyte17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRLCharles River Laboratories International19,70049.34 million48.70 millionOptionableEXASExact Sciences7,200190.89 million188.60 millionOptionableINCYIncyte2,844199.78 million164.22 millionOptionableINCY, CRL, and EXAS HeadlinesRecent News About These CompaniesIncyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic DermatitisMay 7 at 8:50 AM | businesswire.comIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6 at 5:01 PM | businesswire.comWhy Incyte (INCY) is a Top Value Stock for the Long-TermMay 6 at 10:41 AM | zacks.comArgus Research Keeps Their Buy Rating on Incyte (INCY)May 6 at 5:31 AM | theglobeandmail.comGuggenheim Sticks to Its Buy Rating for Incyte (INCY)May 6 at 5:31 AM | theglobeandmail.comHere's Why Incyte (INCY) is a Strong Growth StockMay 5 at 10:45 AM | zacks.com18,960 Shares in Incyte Corporation $INCY Acquired by PFA Pension ForsikringsaktieselskabMay 5 at 5:53 AM | marketbeat.comHorizon Investments LLC Sells 83,430 Shares of Incyte Corporation $INCYMay 5 at 5:53 AM | marketbeat.comIncyte (NASDAQ:INCY) Receives Buy Rating from HC WainwrightMay 5 at 3:58 AM | americanbankingnews.comDanske Bank A S Boosts Stake in Incyte Corporation $INCYMay 5 at 3:50 AM | marketbeat.comWhy Incyte (INCY) is a top momentum stock for the long termMay 4 at 2:57 PM | msn.comWhy Incyte (INCY) is a Top Momentum Stock for the Long-TermMay 4 at 10:51 AM | zacks.comIncyte's (INCY) "Buy" Rating Reaffirmed at HC WainwrightMay 4 at 8:22 AM | marketbeat.comComparing Genprex (NASDAQ:GNPX) & Incyte (NASDAQ:INCY)May 4 at 4:51 AM | americanbankingnews.comNew First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]May 3, 2026 | prnewswire.comIncyte Corporation (NASDAQ:INCY) Given Consensus Recommendation of "Hold" by BrokeragesMay 3, 2026 | americanbankingnews.comIncyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from BrokeragesMay 3, 2026 | marketbeat.comIncyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock RatingsMay 2, 2026 | finance.yahoo.comLMG Wealth Partners LLC Acquires New Holdings in Incyte Corporation $INCYMay 2, 2026 | marketbeat.comSanctuary Advisors LLC Has $3.16 Million Holdings in Incyte Corporation $INCYMay 2, 2026 | marketbeat.comIncyte Gets FDA Approval for Extended-Release Version of Jakafi TreatmentMay 1, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINCY, CRL, and EXAS Company DescriptionsCharles River Laboratories International NYSE:CRL$181.95 +0.22 (+0.12%) Closing price 03:59 PM EasternExtended Trading$181.87 -0.08 (-0.05%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Exact Sciences NASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Incyte NASDAQ:INCY$97.77 -2.08 (-2.08%) Closing price 04:00 PM EasternExtended Trading$97.78 +0.02 (+0.02%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
